Malaria drug: GSK seeks FDA approval of single-dose tafenoquine to treat Plasmodium vivax malaria
by Press Release from Outbreak News Today on (#3989E)
GSK and Medicines for Malaria Venture (MMV) today announced the submission of a new drug application (NDA) by GSK to the United States Food and Drug Administration (FDA), seeking approval of single-dose tafenoquine for the radical cure (prevention of relapse) of Plasmodium vivax (P. vivax) malaria in patients 16 years of age and older. If approved, tafenoquine ["]
The post Malaria drug: GSK seeks FDA approval of single-dose tafenoquine to treat Plasmodium vivax malaria appeared first on Outbreak News Today.